Effectiveness of ovarian age as the background risk for aneuploidy screening in an unselected pregnant population
Por:
Grande M, Sabria-Bach J, Borobio V, Mercadé I, Stergiotou I, Masoller N and Borrell A
Publicada:
1 oct 2016
Ahead of Print:
26 jul 2016
Resumen:
The aim of this study was to assess the performance of first-trimester combined screening when replacing the chronological maternal age by Anti-Mullerian hormo(AMH) and antral follicle count (AFC)-derived ovarian ages, as the background risk in trisomy risk estimation. A total of 639 pregnant women who completed first-trimester combined screening together with AMH and AFC determination were included. Trisomy risks were estimated based on three distinct 'maternal ages' as a-priori risk (chronological age, AMH-and AFC-derived ovarian age). The screening performance was assessed using three different approaches: received operator curve; detection rate and false positive rates for a fixed 1/250 threshold; and detection rates for a fixed 3% false positive rate. A non-significant trend was shown for AMH-derived age for both an increased area under the curve (0.986 versus 0.979) and an increased detection rate (from 83% to 100%) for a 1/250 risk threshold. For a 3% false-positive rate, a non-significant trend for increased detection with the use of both AMH- and AFC-derived ovarian ages was observed (from 67% to 83%). These results indicate that, although ovarian derived ages seem to potentially reflect a more precise background risk for fetal trisomies, the improvement in screening performance is only residual. (C) 2016 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
Filiaciones:
Grande M:
BCNatal, Department of Maternal-Fetal Medicine, Institute Gynecology, Obstetrics and Neonatology, Hospital Clínic Barcelona, Catalonia, Spain
Sabria-Bach J:
BCNatal, Department of Obstetrics and Gynecology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Catalonia, Spain
Borobio V:
BCNatal, Department of Maternal-Fetal Medicine, Institute Gynecology, Obstetrics and Neonatology, Hospital Clínic Barcelona, Catalonia, Spain
Mercadé I:
Department of Biochemistry and Molecular Genetics, CDB, Hospital Clínic Barcelona, Catalonia, Spain
Stergiotou I:
BCNatal, Department of Maternal-Fetal Medicine, Institute Gynecology, Obstetrics and Neonatology, Hospital Clínic Barcelona, Catalonia, Spain
Masoller N:
BCNatal, Department of Maternal-Fetal Medicine, Institute Gynecology, Obstetrics and Neonatology, Hospital Clínic Barcelona, Catalonia, Spain
Borrell A:
BCNatal, Department of Maternal-Fetal Medicine, Institute Gynecology, Obstetrics and Neonatology, Hospital Clínic Barcelona, Catalonia, Spain.
Bronze
|